Pfizer (PFE) Total Current Liabilities (2009 - 2026)

Pfizer has disclosed Total Current Liabilities across 18 years of filings, most recently posting $34.3 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 5.77% year-over-year to $34.3 billion; the TTM figure through Mar 2026 stood at $34.3 billion (down 5.77% YoY), while the FY2025 annual figure was $37.0 billion, down 13.98% from the prior year.
• Total Current Liabilities slipped to $34.3 billion in Q1 2026, from $37.0 billion in the prior quarter.
• Over the last five years, Total Current Liabilities for PFE reached as high as $47.8 billion in Q4 2023 and fell as low as $5.2 billion in Q4 2022.
• The 5-year median for Total Current Liabilities is $37.7 billion (2025), against an average of $37.5 billion.
• The widest YoY moves for Total Current Liabilities: up 494.77% in 2023, down 26.92% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $42.1 billion in 2022, then grew by 13.42% to $47.8 billion in 2023, then slipped by 10.04% to $43.0 billion in 2024, then declined by 13.98% to $37.0 billion in 2025, then fell by 7.13% to $34.3 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $34.3 billion, $37.0 billion, and $36.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.